W2O has announced findings from a research study on consumer attitudes toward data privacy, specifically personal health data.
The study, Consumer Attitudes on Health Care Data Uses and Privacy, was conducted in two waves – before and during the COVID-19 pandemic – to understand the overall perceptions of data privacy, gain insights into consumer awareness about data usage, and better understand consumers’ willingness to share health data.
The findings indicate that before people will be confident in sharing their health data, they need education and information about how their data will be used. Consumers want control over their health data, including a permission-based system to share data, and the ability to opt out at any time. According to the survey, 70% of participants said they believed that health data should either not be shared or shared only with their permission.
Full results of the research study and an infographic can be found here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.